Skip to main content
OpenTrials
Completed

NCT Number: NCT02725879

FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)

It is well documented that thyroid hormones (THs) are involved in energy and lipid metabolism, thermogenesis, and body weight control, acting on several tissues. Thus, any change in thyroid status may affect body weight and metabolic rate. On the other hand, fibroblast growth factor 21 (FGF-21) is a complex hormone involved in energy, lipid, and glucose metabolism, sharing common biochemical pathways and sites of action with THs. FGF-21 is synthesized and acts primarily on the liver, but weaker expression has also been described in muscle, pancreas, and adipose tissue. In addition, FGF-21 acts through endocrine and paracrine mechanisms, regulating metabolic pathways such as fatty acid oxidation, glucose uptake, and thermogenesis. Recent animal and human studies have highlighted a close bidirectional relationship between FGF-21 and THs, partially elucidated. Thyroid hormones regulate the expression of the FGF-21 gene in the liver and can also increase FGF-21 levels in vivo. However, it has also been suggested that some of their key actions are largely independent. Data on FGF-21 levels and their metabolic role in pediatric patients with chronic autoimmune thyroiditis (AIT) are scarce. This study aims to measure FGF-21 serum levels in children and adolescents with Hashimoto's thyroiditis and investigate any possible associations between FGF-21 serum levels and resting metabolic rate (RMR) and levothyroxine (LT4) treatment, or other clinical and biochemical parameters.

Completed

Looking for future studies?

Notify Me

Key information

Age range

5 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

2nd Department of Paediatrics, School of Medicine Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki, Greece

Thessaloniki, 546 21, Greece

About this study

Children and adolescents, aged 5-18 years, will undergo routine screening for chronic autoimmune thyroiditis (AIT) at the Pediatric Endocrinology Outpatient Clinic of "Papageorgiou" General Hospital and "AHEPA" University Hospital of Thessaloniki, Greece. The diagnosis of AIT will be based on the presence of anti-thyroid autoantibodies (Anti-TPOAb and/or Anti-TgAb) and one or more of the following: clinical symptoms of thyroid dysfunction, goiter, or diffuse/irregular hypoechogenicity of the thyroid gland during an ultrasound examination.

All participants should have a normal body mass index (BMI) for their age and sex, be drug-naive for at least 3 months, follow no special diet, and have no chronic and/or acute disease or menstrual disorder. Only those subjects that will start routine LT4 treatment will be reassessed at six months (not the rest participants), with no specific intervention to take place during those six months.

For all participants, a detailed medical history will be recorded. The following parameters will be measured and calculated: age and pubertal stage according to Tanner, height, body weight, Body Mass Index (BMI), waist circumference, hip circumference, mid-upper arm circumference (MUAC), and skinfolds measurement in order to estimate the percentage of body fat (%BF). The resting metabolic rate (RMR) will be measured with a portable device applying indirect calorimetry. Blood samples will be collected after overnight fasting.

The following parameters will be tested in serum: thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase antibody (Anti-TPOAb) titers, thyroglobulin antibody (Anti-TgAb) titers, total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), aspartate aminotransferase (AST), alanine aminotransferase (ALT), γglutamyltransferase (γ-GT), alkaline phosphatase (ALP), applying an automatic chemical analyzer or immunoassay system and analogs reagents that already exist at the hospital. Serum FGF-21 levels will be determined in pg/mL using the Solid Phase Sandwich Enzyme-linked Immunosorbent Assay (ELISA) method according to the manufacturer's protocol.

Additionally, all participants, with the help of their parents and/or caregivers, will complete the Mediterranean Diet Index (KIDMED) at their first visit.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For patients

  • Subjects 5 to 18 years old.
  • First diagnosis of chronic autoimmune thyroiditis (high levels of serum antithyroid autoantibodies anti-TPO, anti-TgAb).

For Controls:

  • Healthy individuals 5 to 18 years old.
  • BMI for age between 15th and 85th percentile (z-score between -1 and +1).

Exclusion criteria

For patients

  • Pre-existing medical treatment for thyroid disease
  • Taking other medications (eg growth hormone, corticosteroids) in the last 3 months.
  • Taking food supplements (eg omega-3 fatty acids, amino acids) in the last 3 months.
  • Concomitant endocrine, metabolic, degenerative, and/or chronic diseases other than obesity (eg diabetes, hyper/ hypercortisolemia, cardiovascular diseases, kidney diseases, myasthenia, neurological diseases, psychiatric disorders eg anorexia nervosa, cancer, anemia, celiac disease, chromosomal abnormalities eg syndrome Turner, Down, etc).
  • Participation in any daily organized physical activity (sport), more than 1 hour per day.
  • Presence of menstrual disorders in adolescent girls.
  • Having any kind of nutrition/dietary intervention (eg weight loss diet, hypocaloric, ketogenic, low-protein diet), in the last 6 months.

For Controls:

  • Presence of any form of thyroid disease.
  • Presence of any endocrine, metabolic, degenerative, and/or chronic disease (eg diabetes, hyper/ hypercortisolemia, obesity, metabolic syndrome, cardiovascular diseases, kidney diseases, myasthenia, neurological diseases, psychiatric disorders eg anorexia nervosa, cancer, anemia, celiac disease, chromosomal abnormalities eg syndrome Turner, Down, etc).
  • Taking any medication (eg growth hormone, corticosteroids) in the last 3 months.
  • Taking food supplements (eg omega-3 fatty acids, amino acids) in the last 3 months.
  • Participation in any daily organized physical activity (sport), more than 1 hour per day. Presence of menstrual disorders in adolescent girls.
  • Having any kind of nutrition/dietary intervention (eg weight loss diet, hypocaloric, ketogenic, low-protein diet), in the last 6 months.

Treatment and study plan

Primary outcomes

  1. Fibroblast Growth Factor 21 (FGF-21)

    Time frame: baseline and 6 months

    serum fibroblast growth factor 21 (FGF-21) levels after an overnight fasting

  2. RMR/Weight/Day

    Time frame: baseline and 6 months

    Resting Metabolic Rate (RMR) per kilogram of body weight per day

Secondary outcomes

  1. SDS BMI

    Time frame: baseline and 6 months

    Standard Deviation Score (SDS) for Body Mass Index (BMI). The standard deviation is a measure of the amount of variation or spread of a set of values around the mean or average. The mean or average value is given an SDS of "0". A negative SDS indicates that the value is below the average or mean and a positive value means it is above the average or mean. SDS correspond to growth chart percentiles as follow:

    -2.68 = 0.4th percentile, -2.01 = 2nd percentile, -1.34 = 9th percentile, -0.67 = 25th percentile, 0 (mean or average) = 50th percentile, +0.67 = 75th percentile, +1.34 = 91st percentile, +2.01 = 98th percentile, +2.68 = 99.6th percentile.

    These percentiles help us understand whether a measurement falls within the normal range for children of the same age and sex. A lower SDS value (closer or lower to -2.68) and a higher SDS value (closer or above +2.68) mean a worst outcome, while a SDS value closer to 0 (mean or average), mean a better outcome.

  2. WAIST C.

    Time frame: baseline and 6 months

    Waist Circumference

  3. HIP C.

    Time frame: baseline and 6 months

    Hip circumference

  4. MUAC

    Time frame: baseline and 6 months

    mid-upper arm circumference

  5. %BF

    Time frame: baseline and 6 months

    Body fat percentage (%BF), is the total mass of fat divided by total body mass. The total body fat includes essential body fat and stored body fat.

  6. FMI

    Time frame: baseline and 6 months

    Fat mass index (FMI) is calculated by dividing the fat weight in kilograms by the height in metres squared.

  7. FFMI

    Time frame: baseline and 6 months

    Fat free mass index (FFMI) is calculated by dividing the free fat weight in kilograms by the height in metres squared.

  8. TSH

    Time frame: baseline and 6 months

    thyroid-stimulating hormone (TSH) after an overnight fasting

  9. FT3

    Time frame: baseline and 6 months

    free triiodothyronine after an overnight fasting

  10. FT4

    Time frame: baseline and 6 months

    free thyroxine (FT4) after an overnight fasting

  11. Glucose

    Time frame: baseline and 6 months

    glucose serum level after an overnight fasting

  12. Insulin

    Time frame: baseline and 6 months

    insulin serum level after an overnight fasting

  13. TC

    Time frame: baseline and 6 months

    Total Cholesterol (TC) serum level after an overnight fasting

  14. TG

    Time frame: baseline and 6 month

    Triglyceride (TG) serum level after an overnight fasting

  15. HDL

    Time frame: baseline and 6 months

    high-density lipoprotein (HDL) serum level after an overnight fasting

  16. LDL

    Time frame: baseline and 6 months

    low-density lipoprotein (LDL) serum level after an overnight fasting

  17. AST

    Time frame: baseline and 6 months

    aspartate aminotransferase (AST) serum level after an overnight fasting

  18. ALT

    Time frame: baseline and 6 months

    alanine aminotransferase (ALT) serum level after an overnight fasting

  19. γ-GT

    Time frame: baseline and 6 months

    gamma gloutamyltransferase (γ-GT) serum level after an overnight fasting

  20. ALP

    Time frame: baseline and 6 months

    alkaline phosphatase (ALP) serum level after an overnight fasting

  21. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)

    Time frame: baseline and 6 months

    HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance, using fasting insulin and blood glucose levels after an overnight fastιng. The meaningful part of the acronym is "insulin resistance". It marks for both the presence and extent of any insulin resistance that you might currently express. It is a way to reveal the dynamic between the baseline (fasting) blood sugar and the responsive hormone insulin.

    Healthy Range: 1.0 (0.5-1.4) Less than 1.0 means you are insulin-sensitive which is optimal. Above 1.9 indicates early insulin resistance. Above 2.9 indicates significant insulin resistance.

  22. Mediterranean Diet Index (KIDMED) Score

    Time frame: baseline

    Mediterranean diet index (KIDMED) score is a questionnaire used to evaluate adherence to the Mediterranean diet in children and adolescents. The KIDMED assesses how well an individual's dietary habits align with the Mediterranean diet.

    Scoring System: 16 questions, each associated with a specific value. The total score ranges from -4 to 12.

    Interpretation:

    ≤3: Very-low-quality diet. 4-7: Need to improve the food pattern to align with the Mediterranean diet.

    ≥8: Optimal adherence to the Mediterranean diet. A lower overall score (≤3) mean a worst outcome (adherence); while a higher overall score (≥8) mean a better outcome (adherence).

  23. Mediterranean Diet Index (KIDMED) Analysis

    Time frame: baseline

    specific foods frequency consumption based on the KIDMED questionnaire

  24. Anti-TPOAb

    Time frame: baseline and 6 months

    antithyroid peroxidase antibody (Anti-TPOAb) titers

  25. Anti-TgAb

    Time frame: baseline and 6 months

    thyroglobulin antibody (Anti-TgAb) titers

Sponsors and collaborators

Lead sponsor

Aristotle University Of Thessaloniki

Other

Registry information

Official study title

Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.

Acronym: THYROMETABOL

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Apr 1, 2016
Registry last updated
Feb 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.